Free Trial

BlueCrest Capital Management Ltd Purchases New Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals logo with Medical background

BlueCrest Capital Management Ltd bought a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 26,200 shares of the company's stock, valued at approximately $916,000.

A number of other institutional investors and hedge funds also recently modified their holdings of IONS. Capital World Investors raised its holdings in Ionis Pharmaceuticals by 46.5% during the 4th quarter. Capital World Investors now owns 11,465,413 shares of the company's stock worth $400,831,000 after buying an additional 3,637,041 shares during the period. Norges Bank bought a new stake in Ionis Pharmaceuticals in the 4th quarter valued at $59,948,000. Vanguard Group Inc. increased its holdings in Ionis Pharmaceuticals by 9.4% during the 4th quarter. Vanguard Group Inc. now owns 16,472,539 shares of the company's stock worth $575,880,000 after purchasing an additional 1,416,781 shares in the last quarter. Aquatic Capital Management LLC bought a new stake in shares of Ionis Pharmaceuticals in the fourth quarter valued at about $8,041,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Ionis Pharmaceuticals during the fourth quarter worth about $7,447,000. 93.86% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Redburn Atlantic initiated coverage on shares of Ionis Pharmaceuticals in a research report on Monday, March 31st. They issued a "neutral" rating and a $39.00 price objective on the stock. Citigroup reduced their target price on Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. StockNews.com raised shares of Ionis Pharmaceuticals to a "sell" rating in a report on Tuesday, March 18th. HC Wainwright increased their price objective on shares of Ionis Pharmaceuticals from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Finally, Guggenheim lowered their price target on shares of Ionis Pharmaceuticals from $65.00 to $64.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Ionis Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $56.67.

Get Our Latest Report on IONS

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, Director Michael R. Hayden purchased 15,000 shares of Ionis Pharmaceuticals stock in a transaction dated Thursday, May 1st. The shares were acquired at an average cost of $31.86 per share, with a total value of $477,900.00. Following the completion of the transaction, the director now owns 50,219 shares in the company, valued at approximately $1,599,977.34. This trade represents a 42.59 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Patrick R. O'neil sold 1,207 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $32.35, for a total value of $39,046.45. Following the completion of the transaction, the executive vice president now directly owns 56,245 shares of the company's stock, valued at $1,819,525.75. The trade was a 2.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 2,027 shares of company stock worth $62,863 in the last three months. Corporate insiders own 2.71% of the company's stock.

Ionis Pharmaceuticals Stock Performance

Shares of IONS stock traded down $1.37 during trading hours on Tuesday, hitting $32.29. 833,505 shares of the company were exchanged, compared to its average volume of 1,553,403. The company has a current ratio of 8.47, a quick ratio of 8.82 and a debt-to-equity ratio of 2.12. Ionis Pharmaceuticals, Inc. has a 52-week low of $23.95 and a 52-week high of $52.34. The stock has a market capitalization of $5.13 billion, a price-to-earnings ratio of -10.59 and a beta of 0.29. The firm has a fifty day simple moving average of $30.60 and a 200 day simple moving average of $33.56.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported ($0.93) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.14. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The company had revenue of $132.00 million during the quarter, compared to analysts' expectations of $144.31 million. During the same quarter last year, the business posted ($0.98) EPS. The firm's revenue for the quarter was up 10.9% compared to the same quarter last year. Research analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

About Ionis Pharmaceuticals

(Free Report)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

Recommended Stories

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Should You Invest $1,000 in Ionis Pharmaceuticals Right Now?

Before you consider Ionis Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.

While Ionis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines